AskBio: AB-1003 trial for LGMD proceeds after positive recommendation

Asklepios Biopharmaceutical (Askbio) has dosed the first participant in the second group of a Phase 1/2 trial testing AB-1003, an experimental gene therapy for limb-girdle muscular dystrophy (LGMD) type 2I/R9. [...] The post AB-1003 trial for LGMD proceeds after positive recommendation appeared first on Muscular Dystrophy News.